Početna › Shizofrenija › Illinois
Kliničke studije za Shizofrenija u državi Illinois
26 studija za Shizofrenija traži sudionike na lokacijama u državi Illinois.
Gradovi u državi Illinois
Službeni tekst studije (engleski)
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
- The University of Chicago, Chicago
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 59 godina · Oba spola · Ažurirano 2. lis 2026. · NCT07853807Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Evanston Hospital, Evanston
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07101094A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Uptown Research Institute, Chicago
U tijeku regrutacijaFaza 1
Od 18 do 55 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT07615426Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0067, Chicago
- Pillar Clinical Research -Chicago, Chicago
U tijeku regrutacijaFaza 3
Od 18 do 65 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT07686263Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Baber Research Group, Naperville
U tijeku regrutacijaFaza 3
Od 5 do 17 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT06229210NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
- Neurocrine Clinical Site, Oak Brook
U tijeku regrutacijaFaza 3
Od 18 do 65 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT07114874A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Local Institution - 0175, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
U tijeku regrutacijaFaza 3
Od 5 do 17 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07424404A Study of Brenipatide in Adult Participants With Schizophrenia
- Re:Cognition Health - Chicago, Chicago
U tijeku regrutacijaFaza 2
Od 18 do 55 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07410507A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT0710511152-week Open Label Safety-Tolerability Study
- Pillar Clinical Research, Chicago
U tijeku regrutacijaFaza 3
Od 18 do 65 godina · Oba spola · Ažurirano 9. ruj 2026. · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Local Institution - 0122, Chicago
- EmVenio Research Center - Prime Healthcare, Chicago
U tijeku regrutacijaFaza 3
Od 13 do 17 godina · Oba spola · Ažurirano 4. ruj 2026. · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Uptown Research Institute, Chicago
U tijeku regrutacijaFaza 1
Od 18 do 55 godina · Oba spola · Ažurirano 2. ruj 2026. · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Chicago
U tijeku regrutacijaFaza 2
Od 18 do 65 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0046, Crystal Lake
- Amr Conventions Research - Illinois, Warrenville
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Chicago
U tijeku regrutacijaFaza 3
Od 10 do 17 godina · Oba spola · Ažurirano 14. kol 2026. · NCT05303064Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- Uptown Research Institute LLC, Chicago
- Pillar Clinical Research LLC, Chicago
U tijeku regrutacijaFaza 2
Od 18 do 65 godina · Oba spola · Ažurirano 29. srp 2026. · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Pillar Clinical Research, Chicago
U tijeku regrutacijaFaza 3
Od 18 do 65 godina · Oba spola · Ažurirano 27. srp 2026. · NCT07363577Transition Care for FEP
- University of Chicago Ingalls Memorial Hospital, Harvey
U tijeku regrutacijaOpažajna studija
Od 18 do 40 godina · Oba spola · Ažurirano 20. srp 2026. · NCT07713849A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Uptown Research Institute, Chicago
U tijeku regrutacijaFaza 2
Od 18 do 55 godina · Oba spola · Ažurirano 23. lip 2026. · NCT07191483A Study to Evaluate the Effect of KarXT on Urological Safety
- Uptown Research Institute, Chicago
- Pillar Clinical Research -Chicago, Chicago
U tijeku regrutacijaFaza 4
Od 18 do 65 godina · Oba spola · Ažurirano 3. lip 2026. · NCT07221877CLOZAPINE Response in Biotype-1
- University of Chicago, Chicago
U tijeku regrutacijaFaza 4
Od 18 do 60 godina · Oba spola · Ažurirano 11. svi 2026. · NCT04580134Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
U tijeku regrutacijaOpažajna studija
Od 18 do 40 godina · Oba spola · Ažurirano 10. ožu 2026. · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Chicago
U tijeku regrutacijaFaza 3
Od 18 do 65 godina · Oba spola · Ažurirano 6. ožu 2026. · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Chicago
U tijeku regrutacijaFaza 3
Od 18 do 65 godina · Oba spola · Ažurirano 12. sij 2026. · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5056, Chicago
U tijeku regrutacijaFaza 2
Od 21 do 55 godina · Oba spola · Ažurirano 26. pro 2025. · NCT06502964Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Chicago
U tijeku regrutacijaFaza 3Zdravi dobrovoljci dobrodošli
Od 18 do 65 godina · Oba spola · Ažurirano 19. pro 2024. · NCT05184335Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.